Sera Prognostics, Inc. (SERA)
| Market Cap | 80.61M |
| Revenue (ttm) | 107,000 |
| Net Income (ttm) | -40.86M |
| Shares Out | 31.00M |
| EPS (ttm) | -1.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,342 |
| Open | 2.56 |
| Previous Close | 2.60 |
| Day's Range | 2.49 - 2.61 |
| 52-Week Range | 1.15 - 11.90 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 9.69 (+272.7%) |
| Earnings Date | Aug 29, 2022 |
About SERA
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The c... [Read more...]
Financial Performance
In 2021, SERA's revenue was $82,000, an increase of 228.00% compared to the previous year's $25,000. Losses were -$35.01 million, 76.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for SERA stock is "Buy." The 12-month stock price forecast is 9.69, which is an increase of 272.69% from the latest price.
News
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 7.50% and 22%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY , Aug. 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Sera Prognostics, Inc. (SERA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Sera Prognostics, Inc. (SERA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2022 Financial Results on August 10
SALT LAKE CITY, July 28, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
SERA PROGNOSTICS TO PRESENT AT 42nd ANNUAL WILLIAM BLAIR GROWTH STOCK CONFERENCE
SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
SERA PROGNOSTICS ANNOUNCES PUBLICATION OF DATA DEMONSTRATING IMPROVED PERFORMANCE OF ITS PRETRM® TEST WITH MORE PRECI...
Results show that the validated proteomics predictor has even greater predictive performance to determine risk of spontaneous preterm birth SALT LAKE CITY , May 19, 2022 /PRNewswire/ -- Sera Prognostics...
SERA PROGNOSTICS PRESENTS DATA DEMONSTRATING THE HEALTH AND ECONOMIC BENEFIT OF PRETRM® TESTING AT ISPOR ANNUAL MEETING
SALT LAKE CITY , May 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
SALT LAKE CITY , May 10, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
SERA PROGNOSTICS AND NEWBORN FOUNDATION PARTNER TO REDUCE RISKS ASSOCIATED WITH PRETERM BIRTH AND IMPROVE HEALTH EQUI...
Project focused on reducing maternal and neonatal mortality and morbidity by mitigating risks associated with unanticipated preterm birth SALT LAKE CITY , May 5, 2022 /PRNewswire/ -- Sera Prognostics In...
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2022 Financial Results on May 10
SALT LAKE CITY , May 2, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD
- Accomplished business and health services leader joins Sera in its quest to improve pregnancy outcomes of mothers and babies - SALT LAKE CITY , April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., Th...
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2021 FINANCIAL RESULTS
SALT LAKE CITY , March 29, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarke...
Sera Prognostics Presents Data Demonstrating Prediction of Preeclampsia Utilizing Protein Biomarker and Clinical Fact...
SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomark...
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2021 Financial Results on Ma...
SALT LAKE CITY , March 18, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...
SERA PROGNOSTICS TO PRESENT AT UPCOMING MARCH INVESTOR CONFERENCES
SALT LAKE CITY, March 3, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
SERA PROGNOSTICS PRESENTATION RESCHEDULED FOR CITI 2022 HEALTHCARE CONFERENCE
SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
SERA PROGNOSTICS TO PRESENT AT UPCOMING FEBRUARY INVESTOR CONFERENCES
SALT LAKE CITY, Feb. 7, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...
SERA PROGNOSTICS ANNOUNCES NEW AGREEMENT WITH MULTIPLAN, EXPANDING PATIENT ACCESS TO THE PRETRM® TEST
SALT LAKE CITY, Feb. 1, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...
SERA PROGNOSTICS ADDED TO NASDAQ BIOTECHNOLOGY INDEX
SALT LAKE CITY, Dec. 15, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
Sera Prognostics Announces Pricing For PreTRM® Test, The Only Broadly Validated Blood Test To Assess Risk Of Preterm ...
SALT LAKE CITY, Dec 2, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...
Sera Prognostics Announces Publication Of Data Confirming The Performance Of The IBP4/SHBG Biomarkers In Diverse Non-...
SALT LAKE CITY, Dec. 1, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker i...
Sera Prognostics Announces The Appointment Of Sandra A.J. Lawrence To The Sera Prognostics Board
SALT LAKE CITY, Nov. 30, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
Sera Prognostics Reports Third Quarter 2021 Financial Results
SALT LAKE CITY, Nov. 9, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...
Sera Prognostics Announces The Appointment Of Zhenya Lindgardt To The Board
SALT LAKE CITY, Nov. 8, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...
Sera Prognostics Appoints Woodrow Myers, MD, MBA As Advisor Of Public And Political Affairs
SALT LAKE CITY, Nov. 4, 2021 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker ...